Weekly Sepsis Research Analysis
This week’s sepsis literature emphasizes translational immunometabolism and engineered nanomedicines as near-term therapeutic opportunities, alongside nanoscale mechanistic insights into organ-specific injury. Key preclinical advances include an LNP‑mRNA strategy to restore a macrophage immunoregulatory enzyme (DPEP2) and a minimal EV scaffold (EN144) enabling IL‑6 decoy EVs that improve survival in murine sepsis. Nanoscale cell–cell communication (Drp1-driven tunneling nanotubes) was identified
Summary
This week’s sepsis literature emphasizes translational immunometabolism and engineered nanomedicines as near-term therapeutic opportunities, alongside nanoscale mechanistic insights into organ-specific injury. Key preclinical advances include an LNP‑mRNA strategy to restore a macrophage immunoregulatory enzyme (DPEP2) and a minimal EV scaffold (EN144) enabling IL‑6 decoy EVs that improve survival in murine sepsis. Nanoscale cell–cell communication (Drp1-driven tunneling nanotubes) was identified as a driver of septic cardiac remodeling, opening new targets for organ-protective interventions.
Selected Articles
1. DPEP2 suppresses hyperinflammation via metabolic reprogramming of macrophages in sepsis.
Integrating patient single‑cell and bulk transcriptomics with mouse models, this study identifies DPEP2 as a negative regulator of sepsis hyperinflammation. EGR1 suppresses Dpep2 transcription, reducing LTD4 catabolism and redirecting eicosanoid flux toward PGE2 with amplified NF‑κB signaling. Lipid nanoparticle delivery of Dpep2 mRNA to monocytes/macrophages mitigated inflammation, organ injury, and improved survival in septic mice, supporting a translational LNP‑mRNA approach to correct immunometabolic dysfunction.
Impact: Provides patient‑informed mechanistic insight and demonstrates an actionable translational therapy (myeloid‑targeted LNP‑mRNA) that reverses maladaptive immunometabolism and improves outcomes in preclinical sepsis—bridging omics discovery to therapeutic intervention.
Clinical Implications: DPEP2 could serve as both a biomarker of hyperinflammation and a therapeutic target. Early‑phase trials testing DPEP2 augmentation (or pharmacologic modulation of LTD4–PGE2 eicosanoid flux) via targeted LNP platforms in carefully phenotyped septic patients are logical next steps, with safety and myeloid specificity prioritized.
Key Findings
- DPEP2 expression is reduced in septic patient monocytes/macrophages and inversely correlates with severity and outcomes.
- EGR1 represses Dpep2 leading to decreased LTD4 cleavage, PGE2 bias, and amplified NF‑κB signaling.
- LNP‑mediated delivery of Dpep2 mRNA to macrophages mitigated inflammation, organ injury, and improved survival in septic mice.
2. Extracellular vesicle engineering using a small scaffold protein.
This engineering study identifies ENPP1 as an EV scaffold and defines a truncated 144‑aa scaffold (EN144) that efficiently loads cargo and displays targeting moieties. EN144 fused to the IL‑6 decoy receptor gp130 produces engineered EVs that potently block IL‑6 trans‑signaling; in murine sepsis models these decoy EVs reduced inflammation and improved survival, establishing a modular platform for cytokine‑targeted EV therapeutics.
Impact: Delivers a minimal, high‑performance EV scaffold enabling targeted cytokine decoy therapies with in vivo survival benefit in sepsis models—an enabling platform for next‑generation biologic delivery.
Clinical Implications: EN144‑based engineered EVs offer a path to tissue‑targeted cytokine neutralization (e.g., IL‑6 trans‑signaling) that could limit systemic immunosuppression and off‑target effects; translation requires PK/PD, manufacturing scale‑up, toxicology, and first‑in‑human studies focused on hyperinflammatory sepsis phenotypes.
Key Findings
- Proteomics identified ENPP1 as a superior EV scaffold; a truncated 144‑aa variant (EN144) efficiently loads diverse cargos.
- EN144 fused to gp130 generates decoy EVs that potently inhibit IL‑6 trans‑signaling.
- EN144-based decoy EVs reduced inflammation and improved survival in murine sepsis models.
3. Cytoskeletal remodeling promotes tunneling nanotube formation and drives cardiac resident cell mitochondrial transfer in sepsis.
Using CLP sepsis models and single‑cell transcriptomics, the authors show that Drp1‑driven cytoskeletal remodeling promotes tunneling nanotube (TNT) biogenesis that mediates mitochondrial transfer among cardiac resident cells. Cardiac‑specific Drp1 knockout disrupted TNT‑mediated exchange, halted metabolic deterioration, and reversed pathological cellular reprogramming, identifying Drp1/TNT networks as nanoscale drivers of septic cardiac remodeling.
Impact: Reveals a previously underappreciated nanoscale mechanism (Drp1‑regulated TNTs) that mediates intercellular mitochondrial trafficking and drives septic cardiac remodeling, offering a novel mechanistic target for organ protection.
Clinical Implications: Targeting Drp1 or TNT biogenesis could become a therapeutic strategy to prevent or reverse septic cardiomyopathy. Translation requires development of pharmacologic modulators, safety profiling, and validation of TNT activity in human cardiac tissue.
Key Findings
- Single‑cell RNA‑seq in CLP sepsis revealed metabolically impaired subpopulations among endothelial cells, fibroblasts, and macrophages with dysfunctional mitochondrial respiration.
- Drp1 interacts with Filamin and Kinesin to coordinate TNT biogenesis and extension, enabling long‑range mitochondrial trafficking.
- Cardiac‑specific Drp1 knockout abrogated TNT‑mediated mitochondrial exchange, halted metabolic deterioration, and reversed cellular reprogramming in sepsis.